These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37356050)

  • 1. The RIG-I agonist M8 triggers cell death and natural killer cell activation in human papillomavirus-associated cancer and potentiates cisplatin cytotoxicity.
    Girone C; Calati F; Lo Cigno I; Salvi V; Tassinari V; Schioppa T; Borgogna C; Lospinoso Severini L; Hiscott J; Cerboni C; Soriani A; Bosisio D; Gariglio M
    Cancer Immunol Immunother; 2023 Sep; 72(9):3097-3110. PubMed ID: 37356050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human Papillomavirus E7 Oncoprotein Subverts Host Innate Immunity via SUV39H1-Mediated Epigenetic Silencing of Immune Sensor Genes.
    Lo Cigno I; Calati F; Borgogna C; Zevini A; Albertini S; Martuscelli L; De Andrea M; Hiscott J; Landolfo S; Gariglio M
    J Virol; 2020 Jan; 94(4):. PubMed ID: 31776268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutically Active RIG-I Agonist Induces Immunogenic Tumor Cell Killing in Breast Cancers.
    Elion DL; Jacobson ME; Hicks DJ; Rahman B; Sanchez V; Gonzales-Ericsson PI; Fedorova O; Pyle AM; Wilson JT; Cook RS
    Cancer Res; 2018 Nov; 78(21):6183-6195. PubMed ID: 30224377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subversion of Host Innate Immunity by Human Papillomavirus Oncoproteins.
    Lo Cigno I; Calati F; Albertini S; Gariglio M
    Pathogens; 2020 Apr; 9(4):. PubMed ID: 32316236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploiting the immunogenic potential of standard of care radiation or cisplatin therapy in preclinical models of HPV-associated malignancies.
    Kowalczyk JT; Fabian KP; Padget MR; Lopez DC; Hoke AT; Allen CT; Hermsen M; London NR; Hodge JW
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36564129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequence-Specific Modifications Enhance the Broad-Spectrum Antiviral Response Activated by RIG-I Agonists.
    Chiang C; Beljanski V; Yin K; Olagnier D; Ben Yebdri F; Steel C; Goulet ML; DeFilippis VR; Streblow DN; Haddad EK; Trautmann L; Ross T; Lin R; Hiscott J
    J Virol; 2015 Aug; 89(15):8011-25. PubMed ID: 26018150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct RIG-I activation in human NK cells induces TRAIL-dependent cytotoxicity toward autologous melanoma cells.
    Daßler-Plenker J; Paschen A; Putschli B; Rattay S; Schmitz S; Goldeck M; Bartok E; Hartmann G; Coch C
    Int J Cancer; 2019 Apr; 144(7):1645-1656. PubMed ID: 30230526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An optimized retinoic acid-inducible gene I agonist M8 induces immunogenic cell death markers in human cancer cells and dendritic cell activation.
    Castiello L; Zevini A; Vulpis E; Muscolini M; Ferrari M; Palermo E; Peruzzi G; Krapp C; Jakobsen M; Olagnier D; Zingoni A; Santoni A; Hiscott J
    Cancer Immunol Immunother; 2019 Sep; 68(9):1479-1492. PubMed ID: 31463653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Human Papillomavirus E6 Oncoprotein Targets USP15 and TRIM25 To Suppress RIG-I-Mediated Innate Immune Signaling.
    Chiang C; Pauli EK; Biryukov J; Feister KF; Meng M; White EA; Münger K; Howley PM; Meyers C; Gack MU
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29263274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of Antitumor Immune Responses by Human Papillomavirus through Epigenetic Downregulation of CXCL14.
    Cicchini L; Westrich JA; Xu T; Vermeer DW; Berger JN; Clambey ET; Lee D; Song JI; Lambert PF; Greer RO; Lee JH; Pyeon D
    mBio; 2016 May; 7(3):. PubMed ID: 27143385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-risk HPV-positive human cancer cell lines show different sensitivity to cisplatin-induced apoptosis correlated with the p21Waf1/Cip1 level.
    Funaoka K; Shindoh M; Yamashita T; Fujinaga K; Amemiya A; Totsuka Y
    Cancer Lett; 1996 Nov; 108(1):15-23. PubMed ID: 8950204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoradiation of cervical cancer cells: targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand.
    Koivusalo R; Krausz E; Ruotsalainen P; Helenius H; Hietanen S
    Cancer Res; 2002 Dec; 62(24):7364-71. PubMed ID: 12499281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity to Fas-mediated apoptosis in high-risk HPV-positive human cervical cancer cells: relationship with Fas, caspase-8, and Bid.
    Hougardy BM; van der Zee AG; van den Heuvel FA; Timmer T; de Vries EG; de Jong S
    Gynecol Oncol; 2005 May; 97(2):353-64. PubMed ID: 15863130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
    Beljanski V; Chiang C; Kirchenbaum GA; Olagnier D; Bloom CE; Wong T; Haddad EK; Trautmann L; Ross TM; Hiscott J
    J Virol; 2015 Oct; 89(20):10612-24. PubMed ID: 26269188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD56-positive lymphocyte infiltration in relation to human papillomavirus association and prognostic significance in oropharyngeal squamous cell carcinoma.
    Wagner S; Wittekindt C; Reuschenbach M; Hennig B; Thevarajah M; Würdemann N; Prigge ES; von Knebel Doeberitz M; Dreyer T; Gattenlöhner S; Klussmann JP
    Int J Cancer; 2016 May; 138(9):2263-73. PubMed ID: 26662627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papillomavirus associated XPF deficiency increases alternative end joining and cisplatin sensitivity in head and neck squamous cell carcinoma.
    Zuo N; Ma L; Liu T; Hu W; Luo Y; Meng H; Ren Q; Deng Y; Wei L; Liu Q
    Oral Oncol; 2023 May; 140():106367. PubMed ID: 36996606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of the RIG-I pathway during influenza vaccination enhances the germinal center reaction, promotes T follicular helper cell induction, and provides a dose-sparing effect and protective immunity.
    Kulkarni RR; Rasheed MA; Bhaumik SK; Ranjan P; Cao W; Davis C; Marisetti K; Thomas S; Gangappa S; Sambhara S; Murali-Krishna K
    J Virol; 2014 Dec; 88(24):13990-4001. PubMed ID: 25253340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumoral HPV16-Specific T Cells Constitute a Type I-Oriented Tumor Microenvironment to Improve Survival in HPV16-Driven Oropharyngeal Cancer.
    Welters MJP; Ma W; Santegoets SJAM; Goedemans R; Ehsan I; Jordanova ES; van Ham VJ; van Unen V; Koning F; van Egmond SI; Charoentong P; Trajanoski Z; van der Velden LA; van der Burg SH
    Clin Cancer Res; 2018 Feb; 24(3):634-647. PubMed ID: 29018052
    [No Abstract]   [Full Text] [Related]  

  • 19. Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.
    Tanaka N; Patel AA; Wang J; Frederick MJ; Kalu NN; Zhao M; Fitzgerald AL; Xie TX; Silver NL; Caulin C; Zhou G; Skinner HD; Johnson FM; Myers JN; Osman AA
    Clin Cancer Res; 2015 Nov; 21(21):4831-44. PubMed ID: 26124202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TMEM45A Affects Proliferation, Apoptosis, Epithelial-Mesenchymal Transition, Migration, Invasion and Cisplatin Resistance of HPV-Positive Cervical Cancer Cell Lines.
    Liu Y; Liu L; Mou ZX
    Biochem Genet; 2022 Feb; 60(1):173-190. PubMed ID: 34143331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.